Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

68-Gallium Dotatate

Phase 2

NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

1

Indications

2

Total Trials

2

Active Trials

0

Competitors

Pipeline

Status by Indication[2][1]

Indication

Pancreatic Neuroendocrine TumorsRecruiting

Pancreatic Neuroendocrine TumorsPhase 2

Recruiting

Timeline

Expected Milestones

Q3 2036

Phase 2Recruiting

Pancreatic Neuroendocrine Tumors

NCT04074135

Clinical

Trials by Indication[1]

Thyroid Carcinoma1 trial

Studies on Thyroid Nodules and Thyroid Cancer

Recruiting·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)··NCT00001160·2,500 enrolled

Pancreatic Neuroendocrine Tumors1 trial

Evaluation of the Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors

Recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT04074135·740 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for 68-Gallium Dotatate. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for 68-Gallium Dotatate. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Related News